Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 14 | 2018 | 300 | 1.360 |
Why?
|
| Lung Neoplasms | 20 | 2018 | 1173 | 1.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2018 | 468 | 0.810 |
Why?
|
| Neoplasm Staging | 12 | 2018 | 800 | 0.280 |
Why?
|
| Carcinoma, Small Cell | 2 | 2010 | 53 | 0.270 |
Why?
|
| Radiotherapy, Conformal | 1 | 2006 | 24 | 0.270 |
Why?
|
| Combined Modality Therapy | 11 | 2010 | 951 | 0.250 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 41 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 57 | 0.240 |
Why?
|
| Esophageal Neoplasms | 3 | 2010 | 150 | 0.220 |
Why?
|
| Survival Rate | 6 | 2010 | 1056 | 0.170 |
Why?
|
| Proteins | 2 | 2018 | 474 | 0.160 |
Why?
|
| Radiotherapy Dosage | 3 | 2010 | 125 | 0.160 |
Why?
|
| Camptothecin | 5 | 2010 | 39 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 66 | 0.150 |
Why?
|
| Deoxycytidine | 4 | 2002 | 83 | 0.150 |
Why?
|
| Paclitaxel | 4 | 2010 | 140 | 0.140 |
Why?
|
| Topotecan | 2 | 2007 | 17 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 160 | 0.130 |
Why?
|
| Carbazoles | 1 | 2015 | 46 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 42 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 100 | 0.120 |
Why?
|
| Piperidines | 1 | 2015 | 123 | 0.120 |
Why?
|
| Aged | 12 | 2018 | 14862 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2010 | 86 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2010 | 17 | 0.110 |
Why?
|
| Middle Aged | 14 | 2018 | 21147 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2018 | 7029 | 0.110 |
Why?
|
| Humans | 27 | 2018 | 68618 | 0.110 |
Why?
|
| Esophagitis | 2 | 2010 | 45 | 0.100 |
Why?
|
| Etoposide | 3 | 2010 | 64 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 331 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 931 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2003 | 88 | 0.100 |
Why?
|
| Cisplatin | 5 | 2010 | 192 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2011 | 111 | 0.090 |
Why?
|
| Palliative Care | 2 | 2003 | 271 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2011 | 239 | 0.090 |
Why?
|
| Vinblastine | 2 | 2007 | 40 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 446 | 0.090 |
Why?
|
| Neoplasms | 3 | 2007 | 1667 | 0.080 |
Why?
|
| Male | 13 | 2018 | 37321 | 0.080 |
Why?
|
| Female | 13 | 2018 | 38074 | 0.080 |
Why?
|
| Carboplatin | 4 | 2010 | 59 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 334 | 0.070 |
Why?
|
| Drug Administration Schedule | 5 | 2007 | 567 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2010 | 3259 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 84 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2010 | 7277 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2010 | 4848 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2004 | 82 | 0.060 |
Why?
|
| Biopsy | 1 | 2006 | 540 | 0.060 |
Why?
|
| Disease Progression | 1 | 2006 | 1038 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2002 | 8 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2002 | 61 | 0.050 |
Why?
|
| Terminal Care | 1 | 2002 | 92 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2002 | 332 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 277 | 0.050 |
Why?
|
| Taxoids | 1 | 2000 | 41 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 508 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 77 | 0.040 |
Why?
|
| South Carolina | 1 | 2006 | 2752 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 1745 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 376 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 38 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2016 | 110 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2016 | 215 | 0.030 |
Why?
|
| Hematologic Diseases | 2 | 2004 | 20 | 0.030 |
Why?
|
| Adult | 5 | 2015 | 21403 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2003 | 714 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 849 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2003 | 349 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 170 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 72 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2003 | 274 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 792 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 238 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 22 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2007 | 40 | 0.020 |
Why?
|
| Bortezomib | 1 | 2007 | 45 | 0.020 |
Why?
|
| Pyrazines | 1 | 2007 | 46 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 848 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 475 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 658 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2007 | 141 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2007 | 190 | 0.020 |
Why?
|
| Prognosis | 2 | 2003 | 2093 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 649 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 629 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 1420 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2004 | 13 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2004 | 228 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2004 | 411 | 0.010 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2002 | 9 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 41 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2003 | 202 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2003 | 238 | 0.010 |
Why?
|
| Nausea | 1 | 2002 | 47 | 0.010 |
Why?
|
| Diarrhea | 1 | 2002 | 63 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 710 | 0.010 |
Why?
|
| Vomiting | 1 | 2002 | 56 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 2358 | 0.010 |
Why?
|
| Bridged-Ring Compounds | 1 | 2000 | 14 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2000 | 58 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 111 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2000 | 84 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 26 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2003 | 756 | 0.010 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1999 | 7 | 0.010 |
Why?
|